264. Long-Term Follow-Up of BIG 1-98
The 12-year results of BIG 1-98 (at 8.1 years median follow-up) were published in Lancet Oncology. This update shows that for postmenopausal women with endocrine-responsive early breast cancer, a reduction in breast cancer recurrence and mortality is obtained by letrozole monotherapy when compared with tamoxifen montherapy. Sequential treatments involving tamoxifen and letrozole do not improve outcome compared with letrozole monotherapy, but might be useful strategies when considering an individual patient’s risk of recurrence and treatment tolerability.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B, for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8•1 years median follow-up. Lancet Oncology 12:1101-1108, 2011 plus webappendix. (BIG 1-98) (Journal impact factor 17.76).
263. Decision Analysis System Used in Trial 33-03
The authors present a reliable and valid coding system for identifying and rating the quality of shared decision making in breast cancer consultations.
Brown RF, Butow PN, Juraskove I, Ribi K, Gerber D, Bernhard J, Tattersall MH. Sharing decisions in breast cancer care: Development of the Decision Analysis System for Oncology (DAS-O) to identify shared decision making during treatment consultations. Health Expect 14:29-37, 2011. (Trial 33-03) (Journal impact factor 2.32).
262. Long-Term Follow-Up of Trial VIII
The primary results of Trial VIII at 12-years median follow-up are presented according to ER-positive and ER-negative subpopulations.
Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Long term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 22:2216-2226, 2011. (Trial VIII) (Journal impact factor 6.45).
261. Composite Measure of Risk in BIG 1-98
In the BIG 1-98 trial, a composite measure of risk based on prognostic features informs treatment selection better than individual biomarkers and supports the choice of five years of letrozole for patients at the highest risk of recurrence, compared with either sequence or tamoxifen monotherapy.
Viale G, Regan MM, Dell’Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22:2201-2207, 2011. (BIG 1-98) (Journal impact factor 6.45
260. Optimal Adjuvant Therapy for Very Young Women
Dr. Prue Francis reviews the current data on optimal therapy for young women with breast cancer.
Francis PA. Optimal adjuvant therapy for very young breast cancer patients. The Breast 20:297-302, 2011. (Review) (Journal impact factor 2.09).
259. Review of Data on Pregnancy after Breast Cancer
This paper raises the most common questions about pregnancy and breast cancer, and uses published data to answer them.
Pagani O, Partridge A, Korde L Larissa Korde, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat 129:309-317, 2011. (Review) (Journal impact factor 4.86).
258. High Dose Chemotherapy Meta-Analysis
This meta-analysis includes patient data submitted by trialists worldwide, including IBCSG data from Trial 15-95.
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes C, Roche H, Tokuda Y, de Vries EGE, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials. J Clin Oncol 29:3214-3223, 2011. (Meta-analysis includes Trial 15-95) (Journal impact factor 18.97).
257. EBCTCG Meta-Analysis of Trials of 5 Year of Tamoxifen
This overview from the EBCTCG includes patient data submitted by trialists worldwide, including IBCSG data from Trial 13-93. The paper reports 15-year risks of breast cancer recurrence and death.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784, 2011. (Meta-analysis includes Trial 13-93) (Journal impact factor 33.63).
256. Long-Term Follow-Up of Trial IX
The primary results of Trial IX at 13-years median follow-up are presented according to ER-positive and ER-negative subpopulations.
Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Ann Oncol 22:1981-1987 2011. (Trial IX) (Journal impact factor 6.45).
255. St. Gallen Consensus Report
Every two years an international panel of experts gather in St. Gallen and the organizers prepare a summary of the conclusions of the consensus meeting which serves as an important resource for the current treatment of early breast cancer.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011. (commentary) (Journal impact factor 6.4).